Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials-Reference-Cited by-同舟云学术

Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials

Published:2017-05-10 Issue:35 Volume:8 Page:59690-59697
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kang Minyong¹,Jeong Chang Wook²,Kwak Cheol²,Ku Ja Hyeon²,Kim Hyeon Hoe²

Affiliation:

1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

2. Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran;BMC Urology;2024-02-20

2. Relative search popularity of five advanced prostate cancer medications using Google Trends;Prostate Cancer and Prostatic Diseases;2023-09-08

3. Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer;Journal of Geriatric Oncology;2023-06

4. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention;Urologic Oncology: Seminars and Original Investigations;2023-03

5. Sarcopenia and the Therapeutic Effects of Androgen Receptor-axis-targeted Therapies in Patients With Castration-resistant Prostate Cancer;In Vivo;2023